Go Pro
NASDAQ:COCH

Envoy Medical Q2 2025 Earnings Report

Envoy Medical logo
$0.69 +0.02 (+2.59%)
As of 01:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Envoy Medical EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.29
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Envoy Medical Revenue Results

Actual Revenue
$0.08 million
Expected Revenue
$0.07 million
Beat/Miss
Beat by +$12.00 thousand
YoY Revenue Growth
N/A

Envoy Medical Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, July 31, 2025
Conference Call Time
7:00AM ET

Envoy Medical Earnings Headlines

Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
Envoy Medical Inc - Ordinary Shares - Class A
See More Envoy Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Envoy Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Envoy Medical and other key companies, straight to your email.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals. The company works closely with healthcare providers to integrate its device into patient care pathways, supporting therapy both in clinical environments and at home.

Headquartered in the Minneapolis–Saint Paul metropolitan area, Envoy Medical currently serves the U.S. market and is evaluating opportunities for expansion into select international regions. Its leadership team combines expertise in medical device development, rehabilitation sciences and commercial operations, backed by private financing aimed at advancing innovative therapies for neurological and musculoskeletal disorders.

View Envoy Medical Profile